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Summary
Thrombomodulin is an endothelial cell surface receptor that trans-
forms the procoagulant thrombin into an anticoagulant. A mutation in
the thrombomodulin gene is a potential risk factor for venous and
arterial thrombosis.
We screened a region within the coding sequence of the thrombo-
modulin gene by single-strand conformation polymorphism analysis
(SSCP) in a pilot study of 104 patients with myocardial infarction and
104 age, sex and race matched controls. We identified a 127G to A
mutation in the gene, which predicts an Ala25Thr Substitution, in 2 out
of 104 patients (l man and l woman) with myocardial infarction but in
no controls. We assessed the risk of myocardial infarction associated
with the mutation in a larger "Study of Myocardial Infarctions Leiden"
(SMILE). Among 560 men with a first myocardial infarction before the
age of 70, 12 were carriers of the Ala25Thr Substitution. In a control
group of 646 men, frequency-matched for age, seven were carriers of
the Ala25Thr Substitution. The allelic frequencies were 1.07% among
patients and 0.54% among controls suggesting risk associated with the
mutation [odds ratio (OR) 2.0, 95% confidence interval (CI) 0.8-5.1].
In patients aged below 50, the predicted risk was almost seven times in-
creased (OR 6.5, CI 0.8-54.2). In the presence of additional risk factors,
such äs smoking and a metabolic risk factor, the predicted risk
increased to 9-fold (OR 8.8, CI 1.8-42.2) and 4-fold (OR 4.4,
CI 0.9-21.3), respectively.
While not conclusive, these results strongly suggest that the
Ala25Thr Substitution is a risk factor for myocardial infarction, espe-
cially in young men, and when in the presence of additional risk factors.
Introduction
Thrombomodulin is an endothelial cell membrane proteoglycan re-
ceptor for thrombin. Once bound to thrombomodulin thrombin loses
most of its procoagulant properties, such äs its ability to coagulate
fibrinogen, to activate factor V and platelets (l, 2). Mechanisms that
counteract coagulation are stii.iulated. The thrombin-thrombomodulin
complex rapidly activates protein C, which with protein S äs cofactor
then cleaves and inactivates the co-factors Va and Villa, with Inhibition
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of thrombin generation äs a result. Besides this mechanism, thrombo-
modulin is known to stimulate the Inhibition of thrombin by antithrom-
bin (3,4). Another function of thrombomodulin is to activate thrombin
activatable fibrinolysis inhibitor (TAFI; also known äs plasma carboxy-
peptidase B or carboxypeptidase U) which inhibits the degradation of
the fibrin network by plasmin (5).
Anticoagulant mechanisms such äs that involving protein C/throm-
bomodulin are of crucial importance in the prevention of thrombosis.
Individuais with mutations in genes that encode protein C, protein S,
antithrombin and factor V Leiden, have an increased tendency toward
venous thrombosis (6-11). Carriers of mutations in genes coding for
other clotting (co)-factors, such äs fibrinogen and prothrombin, may
also be at increased risk for venous (12, 13) and for arterial disease
(14-16).
Mutation in the thrombomodulin gene is also a potential risk factor
for venous and arterial thrombosis. This has not been extensively
investigated, due to an inability to select individuals with an abnormal
phenotype because the protein is integral to the endothelial cell mem-
brane.
To date, a few variations in the thrombomodulin gene have been de-
scribed (17-20). The risk of venous and arterial thrombosis associated
with these mutations has been assessed for some of these in small
groups of patients with varying results (20-25). While certain of these
mutations are associated with thrombosis, raising the possibility of
causality, none of the clinical studies have been large and none of the
mutations have been characterized in detail in in vitro lest Systems.
Further evidence is therefore required to confirm or refute the role of
thrombomodulin mutations in thrombosis.
In this report, we present such evidence. In a pilot study of 104 pa-
tients with myocardial infarction we have screened the 5' and the
coding regions of the thrombomodulin gene by single-strand conforma-
tion polymorphism analysis (SSCP) and have identified a mutation.
In a large case-control "Study of Myocardial Infarctions Leiden"
(SMILE) we evaluated the risk of this particular mutation for myocar-




The patients and controls have been described in a previous report of screen-
mg of the thrombomodulin gene promoter region (25). The patient group
consisted of 104 unselected individuals admitted to hospital who had confirmed
myocardial infarction using WHO cnteria. Controls were matched on a 1:1 ba-
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sis for sex, age and race usmg patients attending the outpatient department ot
Channg Cross Hospital, London, UK, for blood tests. The only cntena used for
exclusion of controls was that they had had venous or artenal thrombosis. This
was ascertained by questionnaire and signed consent was given after the study
had been fully explained. The study was approved by the Ethics Committees of
West Middlesex and Charing Cross Hospitals.
SMILE
The Study of Myocardial Infarctions Leiden (SMILE) is a large population-
based case-control study. Men aged 70 years or less, with a first myocardial
infarction between January 1990 and January 1996 were eligible for this study.
Potential cases were identified from computerized discharge records of an aca-
demic and a general hospital, both in Leiden, the Netherlands. Two of the fol-
lowing three characteristics had to be identifiable in the discharge report or hos-
pital care record to confirm acute myocardial infarction: typical ehest pain,
electrocardiographical changes indicative of evolving myocardial infarction or
a transient rise in cardiac enzymes to more than twice the upper limit of normal.
As a control group, men with an orthopaedic Intervention between January
1990 and May 1996 were invited. The orthopaedic Intervention varied from one
person to another, for example a plaster cast for a ruptured hamstring or a hip
replacement. These controls were identified via the Leiden Anticoagulation
Clinic and had received prophylactic anticoagulation for a few weeks or months
after the orthopaedic event. In the Leiden region it is routine procedure to pre-
scribe anticoagulant treatment to every person who is (partly) immobilized,
temporarily or for a longer period. The controls did not have a history of myo-
cardial infarction and had not used anticoagulants for at least 6 months prior to
participation in this study. The controls were frequency matched to cases on
10-yearagegroups.
Both patients and controls were born in the Netherlands and were hving in
the Leiden region. Excluded were men with renal disease (n = 10), severe
(neuro)psychiatric problems (n = 28), or a life expectancy less than one year
(n = 16). The response among the remaining patients and controls was 84.3%
(560) and 77.0% (646), respectively. The study protocol was approved by the
Ethics Committees of both hospitals.
All individuals completed a questionnaire concerning the presence of cardi-
ovascular risk factors such äs smoking habits and alcohol consumption. For pa-
tients all questions referred to the period prior to their myocardial infarction.
The Quetelet index was derived by dividing weight (kilograms) by squared
height (m2). Individuais were considered obese if their Quetelet index exceed-
ed 30 kg/m-. Medication use and history of diabetes were ascertained by inter-
view with controls and retrieved from discharge letters for patients. A person
was classified äs hypertensive or hypercholesterolemic when he was prescribed
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Fig. l Representation of thrombomodulin gene base changes (upper Ime,
numbered in normal sequence), ammo acid sequences (single letter, lower line,
numbered in c) and restriction enzyme cutting sites (recognition sequences
indicated by bars), described in Methods and Results. a) Normal sequence,
b) mutation at G127A with amino acid Substitution Ala25Thr (A25T), which
abolished a Bstu I site, c) silent nucleotide mutation G129C which introduces
an Acil site
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pertension and hypercholesterolemia were grouped together äs "metabolic risk
factors" (16). Note that the prevalence of "metabolic risk factors" is based upon
drugs prescribed for such conditions and is therefore almost certamly an under-
estimate. This implies that the actual associations between "metabolic risk
factors" and the Ala25Thr Substitution will be larger than the estimates given in
Results.
Blood Collection and DNA Analysis
Pilot study
Blood samples were collected on initial presentation of the patients at the
hospital Accident and Emergency Department, prior to confirmation of diagno-
sis. Genomic amplification, sequencing and SSCP of the thrombomodulin gene
were essentially äs described previously (25). Following the identification of
mutations in the promoter region of the thrombomodulin gene (25) we contin-
ued to screen for mutations in the coding region of the gene. This report is only
concerned with the screening of a fragment which codes for the first 47 amino
acids and 53 bases 5' to the coding region. Primers used for amplification prior
to SSCP were TM5A (sense): 5'-TGT CGC AGT GCC CGC GCT TT-31;
TM5B (antisense): 5'-TCG CAG ATC TGA CTG GCA TT-3'. These primers
resulted in an amplification product of 211 bp. Following an initial denaturation
at 94° C for 4 min, the amplification protocol was 32 cycles of: denaturation at
94° C for 30 s, annealing at 63° C for 30 s, extension at 72° C for 30 s. SSCP
was continued for SOOvh (Phast System, Pharmacia).
SMILE
A morning fasting blood sample was drawn from the antecubital vein in two
Sarstedt Monovette® tubes containing 0.106 mM trisodium citrate. Blood m the
citrated tubes was centrifuged for 10 min at 3000 X g at room temperature.
Genomic DNA was extracted from the white blood cells by a salting-out
method (26). The DNA was stored at 4° C. Amplification of a fragment of the
thrombomodulin gene was performed using polymerase chain reaction (PCR)
with l mg genomic DNA and 0.2 units thermostable Taq DNA polymerase
(Perkm Eimer, New Jersey, USA) in a Barnstead thermocycler (Biomed
GmbH, Germany). The nucleotide sequence of the primers used were respec-
tively: TM5A (sense, äs m pilot study): 5'-TGT CGC AGT GCC CGC
GCT TT-3' and TM5C (antisense): 5'-GCT GGT GTT GTT GTC TCC CGT
AA-3'. The initial cycle consisted of a denaturation step at 95° C for 4 min; this
was followed by 33 cycles of 94° C for 40 s, 60° C for 40 s and 71° C for 2 min.
This results in a fragment of 406 bp coding for a part of the 5' untranslated
region, the signal peptide and amino acids one through 100 of the N-terminal
lectin-like module of the thrombomodulin gene (numbering according to the
amino acid sequence of the mature protein) (27). Ten μΐ of the PCR reactions
were digested with 3.5 units BstU I (Biolabs, New England) for 2 h at 60° C.
DNA fragments were separated by electrophoresis on a 2% agarose gel. The
common G allele coding for Ala25 gave fragments of 190 bp and 18 bp. The
rare A allele coding for Thr25 gave a relevant fragment of 208 bp long.
To distinguish the I27G to A mutation from a possible GCG to GCC poly-
morphism two nucleotides downstream (17), we used Acil (Biolabs, New
England) digestion of the Thr-encoding fragments. Ten μΐ of the PCR reactions
were digested with 1.7 units of Acil overnight at 37° C. In the presence of the
mutation without the polymorphism, the relevant Acil fragment is 98 bp. With-
out the mutation but in the presence of the polymorphism, this results in 58 and
40 bp fragments. All positive samples were directly sequenced for final confir-
mation of the mutation (automated cycle sequencing, Model 373, Applied
Biosystems Ine, with the Support of the Advanced Biotechnology Centre,
Charing Cross Hospital).
All patients and controls were tested for the presence or absence of the
factor V Leiden and prothrombin 20210A mutations, the results of which have
been published elsewhere (15).
Statistical Analysis
Means are presented with Standard deviation (s.d.). An odds ratio (OR) was
calculated äs a measure of relative risk. This odds ratio estimates the risk of a
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myocardial mfarction in the presence of the Ala25Thr mutation relative to its
absence, the reference category. A 95% confidence interval (CI) was calculat-
ed accordmg to the method of Woolf (28). Multiple logistic regression was per-
formed to adjust for age. All computations were carried out usmg the SPSS for
Windows Version 7 0 statistical package.
Results
Pilot Study
A mutation was identified by SSCP, I27G to A predicting Ala25Thr,
in 2 of the 104 patients with myocardial infarction but in none of the
controls, see Figs. l and 2. Unlike rnost of the patients with mutations
in the previous promoter region study (25), both patients were Cauca-
sian, l man (51 years), and l woman (66 years). No other sequence
Variation was identified by SSCP in this region.
SMILE
The characteristics of patients and controls participating in SMILE
are shown in Table 1. The mean age of the 560 patients was 56.2
(s.d. 9.0) years compared to 57.3 (s.d. 10.8) years in 646 controls.
Smoking was confirmed äs a cardiovascular risk factor in this study, be-
ing present in 62.3% of the patients compared to 33.3% in controls.
Overall 19 individuals carried the Ala25Thrthrombomodulin Substi-
tution. All mutations identified by digestion with BstU I were investi-




































* Data refer to the period pnor to myocardial infarction
$ Obesity is present äs the Quetelet Index exceeds 30 kg/m2.
For two individuals length and weight were not available.
§ A person was classified äs hypertensive or hypercholesterolemic
if he was taking specific medications
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F/g. 2 SSCP and sequencing audioradiograph of Ala25Thr (G to A) mutation
compared to normal. Mutation detection by SSCP (upper) and direct sequenc-
ing (lower). The SSCP results demonstrating mobility shifts caused by the
G127A mutation and detected with primers TM5A and TM5B (see Methods)
are illustrated (abnormal band arrowed), while the addition A nucleotide is
arrowed in the sequencing gel
gated further using Acil digestion and confirmed by direct sequencing.
The mutation was found in 12 patients (2.1%) and 7 controls (1.1%),
leading to an odds ratio of 2.0 (CI 0.8-5.1) (Table 2). Adjustment for
age did not affect this result. Thus, the A allele frequency was 1.1%
(CI 0.5-1.7%) among patients and 0.5% (CI 0.1-0.9%) among controls.
No homozygous carriers were found. Based on a supposed A allele
frequency of 1%, the frequency of homozygotes is expected to be about
l in 10,000 individuals, which explains their absence in our study pop-
ulation. One patient, with a myocardial infarction at the age of 44 years,
carried the Ala25Thr thrombomodulin Substitution äs well äs the factor
V Leiden mutation. One control subject carried the Ala25Thr Substitu-
tion äs well äs the prothrombin 2021A allele. After exclusion of persons
with either the factor V Leiden or the prothrombin mutation, the odds
ratio increased to 2.2 (CI 0.8-6.0).
Dividing the group into two age categories, 50 years or above, and
below 50 years of age, resulted in different predicted risks for myocar-
dial infarction in the presence of the Ala25Thr Substitution, Table 2. In
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Cardiovascular risk factor Number of patients Number of controls (%') Odds ratio (95% CI) t Table 3 Risk effect of cardiovascular risk fac-
tors without and with the Ala25Thr Substitution
Non - Smoking
Smoking
Absence of metabolic risk factor























































* percentages are calculated withm each stratum of cardiovascular nsk factor
t odds rabos adjusted for age, with 95% confidonce interval Reference categones are non-carner non-smokörs, and respectively non-
carners with an absence of a metabolic nsk factor
the group 50 years or above (total n = 892) the odds ratio became
1.2 (CI 0.4-3.8), which was unchanged after correction for age, in-
dicating at most a mildly increased risk associated with the Substitution.
However, among 314 men aged less than 50, six patients and one
control carried the thrombomodulin Substitution. This gives an odds
ratio of 6.5 (CI 0.8-54.2), an indication of a strong effect on the risk of
myocardial infarction by the Substitution. When we contrasted the
frequency of carriership among patients aged under 50 and all controls,
to limit the possibility of a coincidentally low frequency among young
controls, the unadjusted odds ratio became 3.7 (CI 1.2-11.2) and
4.2 (CI 1.1-15.9) after age adjustment.
Among smokers with the Ala25Thr Substitution the odds ratio in-
creased about nine-fold compared to non-smokers without the mutation
(OR 8.8, CI 1.8-42.2), Table 3. In comparison, smokers without the ab-
normality had a relative risk of about three (Table 3). A similar indica-
tion of a synergistic effect was found for the presence of one or more
metabolic risk factors together with the Substitution. The single effect
was small without the concomitant presence of the Ala25Thr Substitu-
tion, whereas a marked increase in predicted risk was found when one
or more metabolic risk factors were present in combination with the
Ala25Thr Substitution (OR 4.4, CI 0.9 - 21.3), although the confidence
intervals were wide.
Discussion
We have in the pilot study identified a I27G to A mutation leading to
the Ala25Thr Substitution in the coding region of the thrombomodulin
gene in two patients with myocardial infarction. This mutation was al-
so independently discovered by a Swedish group. They reported this
particular mutation in a case study concerning a 42-year-old Swedish
woman with venous thrombosis in the sinus sagittalis and her 16-year-
old daughter, the latter who had not suffered from any thrombotic event
(19). On the basis of the present large, case-control study SMILE, it ap-
pears that there is an approximate two-fold increased nsk of myocardial
infarction associated with the presence of this Ala25Thr Substitution.
When the mutation is present together with smoking or a metabolic risk
factor, the risk appears to be greatly increased, respectively nine- or
four-fold. The apparent risk associated with the Ala25Thr Substitution
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is most pronounced (~7-fold) in men under the age of 50 years. While
the odds ratio for the mutation conferring risk consistently exceeded
unity, the results are cautiously interpreted here äs suggestive of in-
creased risk, because of the associated wide confidence limits. These
wide limits most probably arise primarily from the low population
prevalence of the mutation, which was unknown at the inception of the
study.
The case-control study SMILE is unique in that it has examined the
relation between a mutation in the thrombomodulin gene and the risk of
myocardial infarction in a large number of patients and controls. Only
two relatively small studies regarding the association of other mutations
in the thrombomodulin gene and the risk of arterial thrombosis have
been reported. In these two studies the importance of the previously
published dimorphism Ala455Val was investigated (21). Among 97
Swedish patients with premature acute myocardial infarction the allele
coding for Ala455 was slightly over-represented, suggesting it äs a risk
factor for myocardial infarction (24). These results were not confirmed,
however, by our study among 104 patients with myocardial infarction
and control subjects matched for age, sex and race (25). Selection and
origin of patients might explain the different results between these two
studies. Three novel thrombomodulin gene promoter mutations were
identified in the latter study, but the study was too small to be able to es-
timate the risks for myocardial infarction (25).
SMILE has suggested that the risk associated with the Ala25Thr
Substitution for myocardial infarction is higher in men than other com-
mon mutations in the genes encoding proteins of the coagulation cas-
cade, such äs the 20210 G to A mutation in the prothrombin gene or the
factor V Leiden mutation 15. The risk of myocardial infarction asso-
ciated with the Ala25Thr Substitution seems to be confined to men be-
low 50 years of age and is approximately sevenfold elevated. This
finding is in accordance with the risk of the Arg353Gln polymorphism
in the gene of clotting factor VII which is also more pronounced in
men under the age of 50 and our recent reports on the effect of factor V
Leiden mutation and factor II 20201A variant in young women (14,
16, 29). Thus, again a genetic risk factor for myocardial infarction
seems to be most evident in the young.
When we consider the predicted risk of myocardial infarction asso-
ciated with the Ala25Thr Substitution in the presence of other cardio-
vascular risk factors, there appears to be a synergistic effect. Its prob-
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able nsk m combmation with the presence of a metabohc nsk factor is
approximately fourfold elevated compared with non-camers without a
metabohc nsk factor More stnking is the nsk associated with the
Ala25Thr Substitution and smoking the nsk is highly mcreased, i e ap-
proximately mnefold It therefore seems that this mutation exerts most
effects in combmation with other nsk factors Synergy has been found
previously for factor V Leiden and factor II20210A and the same car-
diovascular nsk factors in women (14) and men (15)
SMILE included only men, born in the Netherlands The predicted
nsk associated with the Ala25Thr Substitution with respect to myocar-
dial infarction among women or other populations could be dissimilar
The Ala25Thr Substitution was, however, found m one woman m our
pilot study Another pomt to be made is that we only included surviving
patients m our study, an inevitable feature of virtually all case-control
studies Thus, we cannot completely exclude the possible selection on
genotype among survivors of myocardial infarction, men who died
could have had a different frequency of the mutation from survivors,
leadmg to a biased nsk estimate An argument agamst the existence of
such bias, is that surviving a myocardial infarction is dependent on
many other factors, such äs time lag between onset of Symptoms of
myocardial infarction and start of medical interventions e g thrombo-
lytic therapy (30, 31) It does not seem hkely that the Ala25Thr
Substitution would play a major role m this
Thrombomoduhn is compnsed of 5 functional domams (27) Alter-
ations m any one of these domams could conceivably have an effect on
the anticoagulant and antifibnnolyüc functions of thrombomodulm
Indeed, mutation in the thrombomodulm gene could result in dysfunc-
tional thrombomodulm or alter the expression level of the protem on
the endothehum (22) In addition, the susceptibihty of thrombomodulm
to proteolytic degradation by proteases circulatmg in the blood rrught
be changed äs a result of a different molecular structure (24) The
Ala25Thr Substitution is located m the N-termmal lectin-hke module of
thrombomodulm This domam has been imphcated m the constitutive
endocytic routing of thrombomodulm from the cellular membrane and
a Substitution m this region could affect this function (32) However, at
present it cannot be excluded that the G to A mutation causmg the
Ala25Thr Substitution is m linkage disequihbnum with a functional
vanation elsewhere
In conclusion, the results of the two mdependent studies presented
here strongly suggest that the 127G to A mutation m the thrombomodu-
lm gene resultmg m the Ala25Thr mutation mcreases the nsk of myo-
cardial infarction among men The mcreased nsk appears most evident
when in the presence of another cardiovascular nsk factor such äs
smoking or a metabohc nsk factor The results need to be confirmed by
other large studies Future research should be aimed at the nsk m wom-
en, the search for and nsk of other mutaüons m thrombomodulm, their
mteraction with other nsk factors, and the clanfication of functional
aspects of these mutaüons
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